Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma

Allergy and Asthma Proceedings

Volumn 30, Issue 5, 2009, Pages 534-539

  Massanari, Marc ^a   Kianifard, Farid ^a   Zeldin, Robert K ^a   Geba, Gregory P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic asthma; Asthma; Cat allergen; Exacerbations; IgE; Lung function; Omalizumab; Steroid bursts; Symptom scores

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FEL D 1 ALLERGEN; IMMUNOGLOBULIN E; OMALIZUMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ALLERGY; ARTICLE; CAT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; MODERATE PERSISTENT ASTHMA; PRICK TEST; SEVERE PERSISTENT ASTHMA;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CATS; CHILD; DOUBLE-BLIND METHOD; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SKIN TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73249121855     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3245     Document Type: Article

References (31)

1. Arbes SJ Jr, Gergen PJ, Vaughn B, et al. Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 120: 1139-1145, 2007.
2. Lewis SA, Weiss ST, Platts-Mills TAE, et al. The role of indoor allergen sensitization and exposure in causing morbidity in women with asthma. Am J Respir Crit Care Med 165:961-966, 2002.
3. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051, U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, 2007.
4. Arbes SJ Jr, Cohn RD, Yin M, et al. Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: Results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol 114:111-117, 2004.
5. Siebers R, Oldfield K, and Crane J. Child-care center sandpits: a source of cat allergen (Fel d 1). J Allergy Clin Immunol 118:533-534, 2006.
6. Abramson SL, Turner-Henson A, Anderson L, et al. Allergens in school settings: Results of environmental assessments in 3 city school systems. J Sch Health 76:246-249, 2006.
7. Gold DR. Environmental tobacco smoke, indoor allergens, and childhood asthma. Environ Health Perspect 108(suppl 4):643-651, 2000.
8. Heinrich J, Bedada GB, Zock J-P, et al. Cat allergen level: Its determinants and relationship to specific IgE to cat across European centers. J Allergy Clin Immunol 118:674-681, 2006.
9. Chapman MD, and Wood RA. The role and remediation of animal allergens in allergic diseases. J Allergy Clin Immunol 107(suppl 3):S414-S421, 2001.
10. Langley SJ, Goldthorpe S, Craven M, et al. Exposure and sensitization to indoor allergens: Association with lung function, bronchial reactivity and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 112:362-368, 2003.
11. Seppälä U, Hägglund P, Wurtzen PA, et al. Molecular characterization of major cat allergen Fel d 1: Expression of heterodimer by use of a baculovirus expression system. Biol Chem 280:3208-3216, 2005.
12. Leitermann K, and Ohman JL. Cat allergen 1: Biochemical, antigenic, and allergenic properties. J Allergy Clin Immunol 74:147-153, 1984.
13. Morgenstern JP, Griffith IJ, Brauer AW, et al. Amino acid sequence of Fel d 1, the major allergen of the domestic cat: Protein sequence analysis and cDNA cloning. Proc Natl Acad Sci U S A 88:9690-9694, 1991.
14. Ingram JM, Sporik R, Rose G, et al. Quantitative assessment of exposure to dog (Can f 1) and cat (Fel d 1) allergens: Relation to sensitization and asthma among children living in Los Alamos, New Mexico. J Allergy Clin Immunol 96:449-456, 1995.
15. Prussin C, and Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 111(suppl 2):S486-S494, 2003. Erratum in: J Allergy Clin Immunol 112:267, 2003.
16. Rambasek TE, Lang DM, and Kavuru MS. Omalizumab: Where does it fit into current asthma management? Cleve Clin J Med 71:251-261, 2004.
17. Frieri M. Advances in the understanding of allergic asthma. Allergy Asthma Proc 6:614-619, 2007.
18. Strunk RC, and Bloomberg GR. Omalizumab for asthma. N Engl J Med 354:2689-2695, 2006.
19. Babu KS, Arshad SH, and Holgate ST. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin Biol Ther 1:1049-1058, 2001.
20. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190, 2001.
21. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001.
22. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638, 2004.
23. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709-717, 2004.
24. Kianifard F, and Gallo PP. Poisson regression analysis in clinical research. J Biopharm Stat 5:115-129, 1995.
25. Stokes ME, Davis CS, and Koch GG. Categorical Data Analysis Using the SAS System, 2nd ed. Cary, NC: SAS Institute, Inc., 2000.
26. Barnes PJ, and Woolcock AJ. Difficult asthma. Eur Respir J 12:1209-1218, 1998.
27. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 56:279-284, 2001.
28. Matsumoto H, Ishihara K, Hasegawa T, et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: A 4-year longitudinal study. Chest 120:1468-1473, 2001.
29. Busse WW, Massanari M, Kianifard F, et al. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: A pooled analysis. Curr Med Res Opin 23: 2379-2386, 2007.
30. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101:1483-1492, 2007.
31. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113:101-108, 2004.